<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652937</url>
  </required_header>
  <id_info>
    <org_study_id>227RA201</org_study_id>
    <nct_id>NCT01652937</nct_id>
  </id_info>
  <brief_title>BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs</brief_title>
  <acronym>EMBRACE</acronym>
  <official_title>A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BIIB057 in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study designed to evaluate the safety and efficacy of BIIB057 in Subjects with
      Rheumatoid Arthritis who have experienced an Inadequate Response to Disease-Modifying
      Antirheumatic Drugs (DMARDs).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving an ACR20 response (ACR20 = American College of Rheumatology 20% response criteria change from baseline)</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and tolerability of BIIB057 by measuring the incidence of AEs, SAEs and changes in laboratory test results during the study</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with 28-joint count Disease Activity Score with C-reactive protein (DAS28-CRP) &lt;3.2, &lt;2.6, and &lt;2.32</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving ACR50 and ACR70 response</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo + Background Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Background therapy including DMARD(s) approved by protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB057 Dose 1 + Background Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Background therapy including DMARD(s) approved by protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB057 Dose 2 + Background Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Background therapy including DMARD(s) approved by protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB057 Dose 3 + Background Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Background therapy including DMARD(s) approved by protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB057</intervention_name>
    <description>Oral</description>
    <arm_group_label>BIIB057 Dose 3 + Background Therapy</arm_group_label>
    <arm_group_label>BIIB057 Dose 1 + Background Therapy</arm_group_label>
    <arm_group_label>BIIB057 Dose 2 + Background Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo + Background Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult onset RA satisfying 2010 Revised ACR Criteria for the Classification of RA with
             a disease history of at least 6 months

          -  Active RA as defined by: at least 4 swollen joints (based on 28-joint count), at least
             4 tender joints (based on 28-joint count), and high-sensitivity CRP (hsCRP) 10mg/L or
             greater

          -  No prior treatment with biologics

          -  Receiving a DMARD therapy for at least 3 months, using a regimen that has been stable
             for at least 28 days prior to screening

        Exclusion Criteria:

          -  History of inflammatory joint disease other than RA

          -  Abnormal chest X-ray consistent with tuberculosis, malignancy, or infection

          -  History of malignancy, carcinoma in situ, or high-grade dysplasia

          -  History of opportunistic infection, infection requiring treatment, serious local
             infection, recent fever, active herpes zoster or Epstein-Barr virus, or diagnosis or
             family history of Creutzfeldt-Jakob disease.

          -  Clinically significant cardiac disease

          -  Treatment with prednisone &gt;10 mg orally daily

          -  Intra-articular steroid injection within 28 days before screening

          -  Clinically significant abnormality in hematology or blood chemistry values at
             screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 3J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quispamsis</city>
        <state>New Brunswick</state>
        <zip>E2E 4J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>DMARD-IR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

